-- Clinical Activity and Translational Data from IPI-549 in Monotherapy and in Combination with Opdivo Support On-Mechanism Proof of Concept --
-- IPI-549 Plus Opdivo in Combination Expansion Cohorts Demonstrates Clinical Activity in Checkpoint Inhibitor Resistant Indications --
-- Company to Host Investor Event and Webcast Today at 6:30 a.m. ET --
PR Newswire
CAMBRIDGE, Mass., Nov. 10, 2018